compani
must-win oncolog
acquir loxo extend oncolog footprint
announc acquisit loxo oncolog loxo rate
improv oncolog footprint highlight outlook see
team note theme fifteen stock
expect price pressur payer consolid attract biotech
multipl trigger loxo provid vitrakvi first-in-class trk
inhibitor follow-on trk inhibitor note major
deal-valu driven ret inhibitor loxo
acquisit allow deliv four strateg deliver
grow revenu vitrakvi-street global sale ii improv
product deal like accret oper margin
year iii creat long-term valu signific contribut first/best-in-
class asset iv speed life-chang medicin de-risk oncolog asset
loxo deal expect close follow acquisit
aurka click note armo click
recent meet manag see note acknowledg
focus in-licens collabor secur next wave
innov reiter ep risk includ price
pressur esp diabet commerci execution/regulatori clinic trial risk
loxo acquisit repres premium
compani friday close price note press releas
transact subject financ condit use cash
debt fund deal transact close subject
regulatori sharehold approv loxo board alreadi recommend
sharehold tender share signific sharehold aisl
capit stake agre tender share
loxo impact ep spend/account method
plan updat financi outlook report
result februari indic spend would rise
support develop effort loxo asset estim
everi increment expenditur lower ep
conting whether deal account asset acquisit
busi combin lli cfo also comment prior outlook
alreadi assum busi development/acquisit assum
loxo deal modestli dilut ep anticip lli prior non-
gaap ep outlook would like revis
midpoint our/street note previous
see note histori issu conserv rang especi
compani
initi ep rang henc assum room match/over-deliv ep expect
expect deal accret cash basi
loxo acquisit allow deliv commit pursu first/best-in-class oncolog
asset loxo promis line-up asset pursu rang indic loxo
global development/commerci partnership bayer bayn-d rate wherebi bayer
bayer/loxo share global develop cost vitrakvi co-promot loxo/bay us
bayer book sale loxo receiv oper profit loxo also develop second-
gener ret inhibitor patient acquir resist moreov fgfr program focus
tumor alter fibroblast growth factor receptor fgfr
vitrakvi clinic profil support long durat therapi
vitrakvi first-in-class trk inhibitor approv fda tissue-agonist treatment adult/
pediatr patient solid tumor harbor neurotroph receptor tyrosin kinas ntrk
mutat estim trk mutat present solid tumor vitrakvi gener
impress overall/complet respons rate solid tumor patient trk mutat
well-toler profil support long durat therapi note month follow-
durat respons reach trial popul assum vitrakvi also approv
ema base loxo august regulatori submiss
key driver valu lli pursuit loxo
registr phase clinic trial oral ret inhibitor treatment ret solid
tumor medullari thyroid cancer lly/loxo expect registr read-out could
submit regulatori submiss ret signal occur lung
cancer patient thyroid cancer medullari thyroid cancer case overal
estim world-wide incid trk-fusion patient prior clinic studi
shown impress efficaci profil nsclc thyroid medullari thyroid
cancer moreov advers event mostli grade support long
durat therapi number multi-kinas inhibitor clinic develop
anti-ret activ includ merck buy /eisai rate lenvima astrazeneca
azn buy vandetanib takeda rate ponatinib novarti nv rate dovitinib etc
loxo asset boost oncolog pipelin valu
next-gener trk inhibitor current undergo clinic trial
patient previous treat ntrk fusion cancer base clinic develop timelin
lly/loxo expect regulatori action/approv grant orphan
drug design fda competit front trk rtk inhibitor clinic
develop includ daiichi sankyo rate roch rog-ch rate
entrectinib novarti dovitinib rate
loxo trial b-cell leukemia/lymphoma initi
decemb primari complet octob highli select non-
coval btk inhibitor target patient increas resist exist btk-inhibitor
buy imbruvica astrazeneca azn buy calquenc
page
compani
valuat risk
valuat pt assum trade ep reflect premium
us pharma major multipl think premium group justifi given lli
innovation-driven diversifi global volume-driven sale growth oper leverag cash flow
gener price target support discount cash flow dcf intrins valu
risk thesi revolv around clinic regulatori setback commerci execut
global price pressur face patent expir ciali forteo alimta
competit pressur trulic nvo ozemp partli mitig rewind outcom
studi humalog biosimilar insulin lispro expect off-set product launch
compani mention note
loxo oncolog loxo rate
bayer bayn-d rate
eisai rate
takeda rate
novarti nv rate
daiichi sankyo rate
roch rog-ch rate
rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
analyst compens base upon stock price perform qualiti analysi commun skill
overal revenu profit firm includ invest bank revenu
matter polici practic firm prohibit offer favor research specif
research rate specif target price consider induc receipt busi
compens addit associ person prepar research report prohibit own
secur subject compani
rate price target histori compani lly-u
strh rate system equiti secur
dissemin research
creat bluematrix
page
compani
suntrust robinson humphrey strh seek make reason effort provid research report
simultan elig client report avail publish restrict access area
websit elig client request password institut investor corpor
member press may also receiv research via third parti vendor includ thomson reuter
bloomberg factset capit iq addit distribut may done sale personnel via
email fax electron mean regular mail
access third parti vendor research websit http //suntrustlibrari bluematrix com/client/
pleas email research depart
contact strh sale repres
rate system effect oct
strh rate equiti secur
rate rel broader market gener next month unless
buy stock total return expect outperform relev benchmark
hold stock total return expect perform line relev benchmark
next month unless otherwis indic
sell stock total return expect under-perform relev benchmark
next month unless otherwis indic
rate nr strh invest rate opinion stock
coverag suspend cs indic strh rate and/or target price temporarili
suspend due applic regul and/or strh manag discret previous publish
rate target price reli upon
strh analyst price target stock cover unless otherwis indic price
target repres analyst expect stock trade next month unless
otherwis indic analyst believ insuffici valuat driver and/or invest
catalyst deriv posit neg invest view may elect approv strh
research manag assign target price likewis certain stock trade may
exhibit volatil wherebi assign price target would unhelp make invest decis
research manag approv analyst may refrain assign target sub-
legend rate price target histori chart
prior rate system oct
design base total return within period
buy total return low-beta secur
reduc total return neg low beta secur
neutral total return within bound
nr rate strh provid equiti research coverag
page
compani
total return price appreci dividend price target within period unless
otherwis note beta defin secur averag beta less use bloomberg
suntrust robinson humphrey rate distribut
